Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.73 |
| ▸ | GFER | P55789 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27999264 | 0.87 | KMT2A (0.66) | KMT2AMEN1MAPK10GFERRAB9A | |
| SCHEMBL3279571 | 0.85 | MEN1 (1.00) | KMT2AMEN1MAPK10GFERRAB9A | |
| SCHEMBL2501726 | 0.78 | KMT2A (0.70) | KMT2AMEN1MAPK10GFERRAB9A | |
| SCHEMBL221242 | 0.78 | KMT2A (0.76) | KMT2AMEN1MAPK10GFERRAB9A | |
| SCHEMBL29391624 | 0.78 | KMT2A (0.76) | KMT2AMEN1MAPK10GFERRAB9A | |
| SCHEMBL30167997 | 0.78 | MEN1 (0.76) | KMT2AMEN1MAPK10GFERRAB9A | |
| SCHEMBL3265731 | 0.78 | MEN1 (0.76) | KMT2AMEN1MAPK10GFERRAB9A | |
| SCHEMBL32674561 | 0.77 | MAPK10 (0.53) | KMT2AMEN1MAPK10GFERL3MBTL1 | |
| SCHEMBL7985717 | 0.76 | KMT2A (0.73) | KMT2AMEN1MAPK10GFERRAB9A | |
| SCHEMBL7941542 | 0.76 | MAPK10 (0.73) | KMT2AMEN1MAPK10GFERRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63039862-A | — | — | None | — | — | JP | disclosed |
| US-12250875-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240122061-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-04-11 | — | — | US | disclosed |
| US-11930699-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-03-12 | — | — | US | disclosed |
| CN-112390829-A | Organic electroluminescent material and device | 环球展览公司 | 2021-02-23 | — | — | CN | disclosed |
| US-20210050532-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210050532-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2021-02-18 | — | — | US | disclosed |
| EP-2376455-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010077992-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| JP-S6339862-A | PYRIDYLAMINOPHENOL DERIVATIVE | OTSUKA PHARMACEUT FACTORY INC | 1988-02-20 | — | — | JP | disclosed |
| US-4297363-A | 2-Amino-3(4 or 5)-(pyridinyl)phenols and their use as cardiotonics | STERLING DRUG INC. (US) | 1981-10-27 | — | — | US | disclosed |
| US-3960886-A | Substituted N-arylanilines | STERLING DRUG INC. (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12250875-B2 | Organic electroluminescent materials and devices | L1CAM, SOD1, EPCAM | KMT2A 3799/4885MEN1 1625/4885MAPK10 1412/4885 |
| US-11930699-B2 | Organic electroluminescent materials and devices | L1CAM, EPCAM, LEF1 | KMT2A 3150/4885MEN1 961/4885MAPK10 1988/4885 |
| US-20210050532-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | L1CAM, EPCAM, LEF1 | KMT2A 3150/4885MEN1 961/4885MAPK10 1988/4885 |
| US-20240122061-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | L1CAM, SOD1, EPCAM | KMT2A 3799/4885MEN1 1625/4885MAPK10 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.